Finnish genomic data management solutions company BC Platforms announced today that it has closed a 9 million euros (10 million USD) Series B round. The round was led by Swiss Debiopharm Innovation Fund together with a Finnish venture capital and private equity company Tesi, and was supported by BC Platforms’ existing investors.
BC Platforms will use the funds to grow its existing genomic data management software business worldwide and launch new technologies already this year. To date, the company operates in over 50 leading international institutions in 19 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver.
Tero Silvola, CEO at BC Platforms, said: ‘We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round. This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative.’
Founded in 1997, BC Platforms has a strong scientific heritage underpinned by 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms’ vision is to provide the world’s leading analytics platform for healthcare and industry, with access by 2020 to over 5 million subjects’ diverse genomic and clinical data and samples consolidated from a global network of biobanks.
Earlier this month the company announced it has been selected as a SME partner for Horizon 2020 ESCAPE-NET Project, a European public-private Consortium, to build a clinical-genomic biobank of sudden cardiac arrest (SCA) patients to facilitate research for SCA prevention.